Project Grant SB1AI186689
Award Date
7/24/25
Completion Date
6/30/28
Dollars Obligated
$999K
Federal Agency
National Institute of Allergy and Infectious Diseases
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
Maryland, EE. UU.
Similar Awards
This Project Grant award of $181,861, provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), will support research conducted by Duke University to develop novel, rapid, and noninvasive diagnostic and prognostic biomarkers for invasive aspergillosis (IA) in immunocompromised patients. The key objectives are to derive and optimize a diagnostic host gene expression signature of IA, enroll and serially...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $299,170 Project Grant under the Allergy and Infectious Diseases Research (CFDA 93.855) program to Latde Diagnostics Corp., a woman-owned small business, to develop a rapid, equitable, lateral flow-based antibiotic susceptibility test (AST) for urinary tract infections (UTIs). The goal of this Phase I project is to demonstrate the feasibility of the Metabolic Amino Acid Phenotyping (MAAP) test kit to provide rapid AST...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $300,000 to Baebies, Inc. to develop a rapid, point-of-care diagnostic test to identify viable sexually transmitted infections (STIs). The goal is to reduce overtreatment and prevent emerging antibiotic resistance. In Phase I, the company will develop viability PCR (V-PCR) assays for Chlamydia trachomatis and Neisseria...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $490,093 to the University of Maryland, College Park to develop a rapid antibiotic susceptibility testing platform. The platform will isolate bacteria directly from whole blood, identify pathogens, and evaluate their antibiotic response within 75 minutes, enabling clinicians to quickly determine appropriate targeted...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $429,244 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to Sherlock Biosciences, Inc. to develop a power-free, molecular diagnostic device that can detect Chlamydia trachomatis and Neisseria gonorrhoeae from self-collected vaginal swabs. The project aims to create an accurate, easy-to-use, and accessible at-home test for these sexually transmitted infections without requiring...
The National Institute of Allergy and Infectious Diseases (NIAID), part of the U.S. Department of Health and Human Services, has awarded a $300,156 Project Grant under the Allergy and Infectious Diseases Research (CFDA 93.855) program to Intact Genomics Inc., a minority-owned small business. The funding will support research to identify new antifungal compounds with novel mechanisms of action from filamentous fungi. The key objectives are to demonstrate the use of Aspergillus nidulans as a...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $249,749 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to The University of Iowa. The grant supports research to develop a new approach for analyzing the transcriptional control of virulence in the fungal pathogen Aspergillus fumigatus, a leading cause of life-threatening infections in immunocompromised patients. The research aims to express a nanobody-E3 ligase fusion protein...
The National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), awarded a $300,000 Project Grant to Electronic Biosciences, Inc. to develop a novel point-of-care technology for monitoring immunosuppressant drug levels. The key product being developed is a portable, fingerstick-based testing system that can provide convenient and frequent immunosuppressant drug level measurements. This will enable more precise dosing for...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $628,726 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to Priogen Corp. to develop a portable, microfluidic device called Micro-QUIC for the rapid detection of misfolded prion proteins that cause transmissible spongiform encephalopathies (TSEs). The 2.5-month project, starting on May 15, 2025, aims to: (1) optimize the Micro-QUIC assay to distinguish between native and misfolded...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), will support the development of a novel universal rapid test for HIV diagnosis. IGE Immunodiagnostics & Therapeutics, LLC, a minority-owned small business, will receive $294,948 to adapt their existing HIV ELISA test into a 5th generation antigen/antibody combination rapid test format. The goal is to create a simple, rapid,...